Volume 23, 2016
|Number of page(s)||6|
|Published online||21 July 2016|
Lack of artemisinin resistance in Plasmodium falciparum in northwest Benin after 10 years of use of artemisinin-based combination therapy
Absence de résistance à l’artémisinine chez Plasmodium falciparum dans le Nord-ouest du Bénin après dix ans d’utilisation de combinaisons thérapeutiques à base de dérivés d’artémisinine
Unité d’Enseignement et de Recherche en Parasitologie – Mycologie/Faculté des Sciences de la Santé ; 01 BP
2 Laboratoire du centre de lutte intégrée contre le paludisme ; 01 BP 188 Cotonou, Bénin
3 Institut de Recherche pour le Développement. UMR 224-MIVEGEC ; 08 BP 841 Cotonou, Bénin
4 Laboratory of Parasitology Mycology, Aristide le Dantec Hospital, BP 16477 Dakar, Senegal
5 UMR 216 MERIT-IRD Parasitology Department Noguchi Memorial Institute for Medical Research College of Health Sciences, University of Ghana, P.O. Box LG581 Legon, Accra, Ghana
6 Centre de santé de la Commune de Djougou, 02 BP 681 Porto Novo, Benin
7 Centre de santé de la Commune de Cobly, BP 40 Tanguiéta, Bénin
* Corresponding author: firstname.lastname@example.org
Accepted: 28 June 2016
Aim: In Benin, artemisinin-based combination therapy (ACT) has been recommended as the first-line treatment for uncomplicated Plasmodium falciparum malaria since 2004. The emergence in Southeast Asia of parasites that are resistant to artemisinins poses a serious threat to global control of this disease. The presence of artemisinin resistance genotypes in parasite populations in Benin is currently unknown. The present study investigated the prevalence of relevant K13-propeller gene polymorphisms in parasite isolates from the north-western region of Benin.
Method: Plasmodium falciparum isolates were collected from children with a confirmed diagnosis of malaria aged 6 months to 5 years in two towns, Cobly and Djougou, in the north-western part of Benin. The study was conducted during the rainy season from July to November 2014 in local health facilities. The K13-propeller gene was amplified in parasite isolates using nested PCR and subsequently sequenced.
Results: A total of 108 children were recruited into the study. The efficiency of amplification reactions was 72% (78/108). The propeller domain of the K13 gene was successfully sequenced in 78 P. falciparum isolates; all of them were wild type with no polymorphisms detectable.
Conclusion: The absence of mutations in the K13 gene indicates that P. falciparum parasite populations in the study area are still fully susceptible to artemisinins.
Contexte : Au Bénin, depuis 2004, les combinaisons thérapeutiques à base d’artémisinine ont été recommandées comme traitement de première intention du paludisme à Plasmodium falciparum non compliqué. L’émergence en Asie du Sud-Est de parasites qui sont résistants à l’artémisinine pose une menace sérieuse pour la lutte mondiale contre cette maladie. La présence de génotypes de résistance à l’artémisinine dans les populations de parasites au Bénin est actuellement inconnue. Cette étude a étudié la prévalence des polymorphismes du gène K13-propeller chez des parasites isolés de la région nord-ouest du Bénin.
Méthodes : Les isolats de Plasmodium falciparum ont été recueillis auprès d’enfants ayant un diagnostic confirmé de paludisme, âgés de 6 mois à 5 ans, dans deux villes, Cobly et Djougou, dans la partie nord-ouest du Bénin. L’étude a été menée pendant la saison des pluies de juillet à novembre 2014 dans les établissements de santé locaux. Le gène K13-propeller a été amplifié dans les isolats de parasites par PCR imbriquée, et ensuite séquencé.
Résultats : Un total de 108 enfants a été recruté dans l’étude. L’efficacité des réactions d’amplification a été de 72 % (78/108). Le gène K13-propeller a été séquencé avec succès dans 78 isolats de P. falciparum ; tous étaient de type sauvage sans polymorphisme détectable.
Conclusion : l’absence de mutations dans le gène K13 indique que les populations du parasite P. falciparum dans la zone d’étude sont encore pleinement sensibles aux artémisinines.
Key words: Plasmodium falciparum / Malaria / Resistance / Artemisinin / K13 propeller / Benin
© A. Ogouyèmi-Hounto et al., published by EDP Sciences, 2016
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Artemisinin-based combination therapies are recommended by the World Health Organization (WHO) as first-line treatment for uncomplicated falciparum malaria in all areas in which malaria is endemic . In 2004, as a result of high failure rates of treatment recorded with chloroquine and sulphadoxine-pyrimethamine (unpublished data from the National Malaria Control Programme), the Beninese National Malaria Control Programme implemented artemisinin-based combination therapy (ACT) as the first-line treatment for uncomplicated malaria. The artemether-lumefantrine combination was thus deployed throughout the country in health facilities.
Currently, the different ACTs in use remain highly effective for the treatment of malaria in Africa, as demonstrated both by rapid parasite clearance and low rates of recrudescence after therapy in clinical trials, as well as by the high rates of sensitivity of clinical isolates ex vivo [3, 16, 19, 27, 31, 35]. The first clinical cases of artemisinin resistance in western Cambodia were reported in 2008 , and Plasmodium falciparum with reduced in vivo susceptibility to artesunate was reported in 2009 [8, 9]. Emergence of resistance was subsequently reported in neighbouring regions [2, 11, 25]. These recent developments have grave implications for public health, since artemisinin derivatives are the mainstay of anti-malarial treatment worldwide. Hence the spread of ACT resistance could be catastrophic for malaria control and elimination efforts around the globe.
Despite the absence, thus far, of mutations associated with artemisinin resistance in P. falciparum isolates from different areas of sub-Saharan Africa [7, 20], previous experience with the spread of chloroquine and sulphadoxine-pyrimethamine resistant parasites from Asia to Africa [18, 33] demonstrates that the spread of drug resistance is likely, and that vigilant surveillance for resistant parasites is warranted. Recently, mutations in the propeller domain of the K13 gene were identified as candidate molecular markers of artemisinin resistance associated with slow parasite clearance rates [1, 6, 17, 28]. These associations indicate that mutations in the K13 propeller (especially C580Y, R539T and Y439H) are important determinants of artemisinin resistance. These markers could therefore serve as a tool to monitor resistance to ACT. Although ACT remains highly efficacious for the treatment of falciparum malaria, and delayed parasite clearance after ACT has not been noted in Benin [15, 22], the molecular epidemiology of artemisinin resistance genotypes in Benin parasite populations is unknown. The aim of the study described here was to characterise the variability of the K13 gene for the first time in Benin.
The study was conducted in Benin during the rainy season between July and November 2014, in two towns named Djougou, situated 450 km from Cotonou (the economic capital), and Cobly, 643 km from Cotonou. At the two sites, malaria transmission occurs from May to November during the rainy season. P. falciparum is the predominant parasite species transmitted by Anopheles gambiae (85%) and An. arabiensis (15%) . The prevalence of P. falciparum infection in the general population was 19.1% in Djougou and 18% in Cobly (unpublished data).
Plasmodium falciparum isolates were obtained from children diagnosed with malaria who had lived in the area of the study sites for more than a period of 6 months and had not travelled during the previous month. Children visiting the health facilities in the study area, aged 6 months to 5 years, and who met the criteria below were enrolled in the study: (i) fever (axillary temperature ≥ 37.5 °C) or a history of fever within the past 48 h, (ii) P. falciparum mono-infection with parasite density ≥1,000 asexual forms per microlitre, identified by microscopy on blood smears; and (iii) written informed consent from parents. Venous blood from children fulfilling the above criteria was collected. Thick and thin blood smears were prepared, stained with 10% Giemsa and examined to determine P. falciparum density and to confirm mono-infection by P. falciparum. All thick blood smears were examined against 500 leucocytes. Parasite densities were recorded as the number of parasites/μL of blood, assuming an average leucocyte count of 8,000/μL of blood. All slides were read in the laboratories of the health centres, with external quality control performed on 10% of the negative slides and all positives in the reference Parasitology Laboratory of the Centre National Hospitalo-Universitaire in Cotonou. Evaluation of K13-propeller polymorphisms was performed using the same venous blood sample used for diagnostic analysis stored as spots on filter paper. All malaria-infected patients, based on microscopy results, were treated with standard doses of artemether/lumefantrine according to the national malaria treatment policy based on ACT.
Parasite DNA was extracted from filter paper using the Chelex method . The propeller domain of the K13 gene was amplified by nested PCR using the following primers: for the primary PCR (K13_PCR_F 5′-G GGAATCTGGTGGTAACAGC-3′ and K13_PCR_R 5′-C GGAGTGACCAAATCTGGGA-3′) and for the nested PCR (K13_N1_F 5′-GCCTTGTTGAAAGAAGCAGA-3′ and K13_N1_R 5′-GCCAAGCTGCCATTCATTTG-3′). The reaction volume and amplification programme used were reported previously . Amplified products were bi-directionally sequenced by Sanger sequencing using BigDye® v3.1 from ThermoFisher Scientific by Beckman Coulter Genomics. The sequence reactions were then run on an ABI3730xl following the manufacturer’s protocols. The propeller domain of the K13 sequence data for single nucleotide polymorphisms (SNPs) was analysed using Geneious software (www.geneious.com). A cut-off of quality score HQ > 30% (the percentage of untrimmed bases that are high quality) was applied to all sequences. Sequences were assembled using the de novo assembly method and aligned to the reference K13 annotated Plasmodium falciparum 3D7 (PF3D7-1343700). The polymorphism search was limited to inside CDS sequences. A search was performed for the mutations described in Asia and in the previous study [13, 14, 29].
Ethical approval: The study obtained the ethical approval of the National Ethics Committee for Health Research of Benin.
During the study period, a total of 225 potentially eligible patients were screened for participation in the study. Following application of inclusion criteria, a total of 108 participants were enrolled in the study. Children’s ages ranged from 6 months to 5 years (mean age: 31.6 ± 0.4 months). Parasite density ranged from 1,028 to 192,715 parasites/μL with a geometric mean density of 16,562 [9,909; 27,681]. Parasite DNA from the 108 P. falciparum isolates was analysed for pfK13 genes. The efficiency of amplification reactions was 72.2% (78/108).
The propeller domain of the K13 gene was successfully sequenced in 78 P. falciparum isolates. After alignment with PF3D7-1343700, all the strains were found to be wild type having no polymorphism previously found in the K13 gene.
In Benin, ACT was introduced as the first-line treatment for uncomplicated P. falciparum malaria in 2004. Although this treatment remains highly efficacious, it is important to monitor the potential presence of artemisinin-resistant P. falciparum parasite populations. The fact that only 72% of included samples were genotyped could be explained by the sensitivity of the PCR method used, because we did not analyse samples with low parasitaemia.
In this study, we did not find any mutation in the propeller part of the gene, as was the case in the Chatterie study in India . Clinical artemisinin resistance is defined as a reduced parasite clearance rate, expressed as an increased parasite clearance half-life or a persistence of microscopically detectable parasites on the third day of ACT. The half-life parameter correlates strongly with results from the in vitro ring-stage survival assay. The absence of mutations in the K13 gene of parasite strains isolated in Benin confirms the results of the therapeutic efficacy tests, conducted at the same study sites, where adequate clinical and parasitological response was 100% after PCR correction . Thus, after 10 years of ACT use, no polymorphisms have appeared in the K13 gene, suggesting that P. falciparum populations in the north-western part of Benin are still effectively susceptible to artemisinin. However, a larger sample size with extension into other parts of the country, including the south where drug pressure is higher , would allow us to draw better conclusions in this context. Artemisinin resistance, with delayed clearance of parasites after treatment with artemisinin monotherapy or artemisinin combination therapies (ACTs), is of great concern but has not yet been documented in sub-Saharan Africa, where speed of clearance of parasites after treatment with ACTs has generally been within the expected range [3, 10, 24, 31]. Small numbers of parasites with K13-propeller gene polymorphisms have been described in some countries in Africa, but importantly these were not the mutations previously associated with drug resistance in Southeast Asia [7, 20, 30]. The absence thus far of K13 resistance-associated mutants from Southeast Asia in Africa is promising, but continuous surveillance for the emergence of resistance should be implemented to enable early detection. The use of molecular markers such as K13 mutations is nowadays a cornerstone of malaria surveillance programmes, but potential differences between African and Asian K13-mutant parasites should be taken into account. The polymorphisms associated with artemisinin resistance in P. falciparum in Southeast Asia are not present in sub-Saharan Africa, but numerous K13-propeller coding polymorphisms have been documented in Africa [12–14, 24, 29]. Although their distributions do not support a widespread selective sweep for an artemisinin-resistant phenotype, the impact of these mutations on artemisinin susceptibility is unknown and will require further characterisation. Longitudinal studies conducted in Kenya [4, 20] showed that parasites from only one of 32 patients carried a mutation (at codon 578 (A578S)) in the propeller region of the pfK13 gene, despite evidence of longer than normal parasite persistence in over 30% of children. To identify K13 polymorphisms that affect artemisinin sensitivity in Africa, clinical trials should be supplemented with in vitro and molecular studies, providing additional data to strengthen confidence that observed mutations are associated with slowed parasite clearance.
In this study, the absence of mutations in the K13-propeller gene suggests that artemisinin resistance is not a problem in Benin. However, similar studies from different parts of the country with a larger number of samples will be helpful to ascertain the emergence of artemisinin resistance, if any. In addition, routine monitoring and surveillance, as recommended by the WHO global plan for artemisinin resistance containment, should be continuously strengthened. Moreover, this study contributes to the ongoing surveillance of suspected artemisinin resistance parasites in Africa by providing baseline data on K13-propeller mutations in Benin.
The authors declare no conflict of interest in relation with this paper.
We are grateful to the children who participated in the study, as well as to their mothers. We are pleased to thank caregivers from Djougou and Cobly health services. This work was integrated into the PALEVALUT project, funded by the 5% – Expertise France Initiative. This funding contributed to data collection, laboratory testing and payment of investigators.
- Ariey F, Witkowsky B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Ménard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Ménard D. 2014. A molecular marker of artemisinin resistant Plasmodium falciparum. Nature, 505, 50–55. [CrossRef] [PubMed] [Google Scholar]
- Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ. 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine, 371, 411–423. [CrossRef] [PubMed] [Google Scholar]
- Assefa A, Kassa M, Tadese G, Mohamed H, Animut A, Mengsha T. 2010. Therapeutic efficacy of Artemether/Lumefantrine (Coartem®) against Plasmodium falciparum in Kersa, South West Ethiopia. Parasites & Vectors, 3, 2–9. [CrossRef] [PubMed] [Google Scholar]
- Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK, Omar SA, Shekalaghe SA, Kaur H, Ndaro A, Chilongola J, Schallig HD, Sauerwein RW, Hallett RL, Bousema T. 2013. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. Journal of Infectious Diseases, 208, 2017–2024. [CrossRef] [Google Scholar]
- Chatterie M, Ganguly S, Saha P, Bankura B, Basu N, Das M, Guha SK, Maji AK. 2015. No polymorphism in Plasmodium falciparum K13 propeller gene in clinical isolates from Kolkata, India. Journal of Pathogens, 2015, 374354. [PubMed] [Google Scholar]
- Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, Al Saai S, Phyo AP, Moo CL, Lwin KM, McGready R, Ashley E, Imwong M, Stepniewska K, Yi P, Dondorp AM, Mayxay M, Newton PN, White NJ, Nosten F, Ferdig MT, Anderson TJ. 2012. A major genome region underlying artemisinin resistance in malaria. Science, 336, 79–82. [CrossRef] [PubMed] [Google Scholar]
- Cooper RA, Conrad MD, Watson QD, Huezo SJ, Ninsiima H, Tumwebaze P, Nsobya SL, Rosenthal PJ. 2015. Lack of artemisinin resistance in Plasmodium falciparum in Uganda based on parasitological and molecular assays. Antimicrobial Agents and Chemotherapy, 59, 5061–5064. [CrossRef] [PubMed] [Google Scholar]
- Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, Wellems TE, Ringwald P, Newman RD, Plowe CV. 2011. The threat of artemisinin-resistant malaria. New England Journal of Medicine, 365, 1073–1075. [CrossRef] [Google Scholar]
- Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine, 361, 455–467. [CrossRef] [PubMed] [Google Scholar]
- Hamainza B, Masaninga F, Moonga H, Mwenda M, Chanda-Kapata P, Chalwe V, Chanda E, Kamuliwo M, Babaniyi OA. 2014. Therapeutic efficacy of artemether–lumefantrine on treatment of uncomplicated Plasmodium falciparum mono-infection in an area of high malaria transmission in Zambia. Malaria Journal, 13, 430. [CrossRef] [PubMed] [Google Scholar]
- Hien TT, Thuy-Nhien NT, Phu NH, Boni MF, Thanh NV, Nha-Ca NT, Thai LH, Thai CQ, Toi PV, Thuan PD, Long LT, Dong LT, Merson L, Dolecek C, Stepniewska K, Ringwald P, White NJ, Farrar J, Wolbers M. 2012. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province. Vietnam. Malaria journal, 11, 355. [CrossRef] [Google Scholar]
- Huang B, Deng C, Yang T, Xue L, Wang Q, Huang S, Su XZ, Liu Y, Zheng S, Guan Y, Xu Q, Zhou J, Yuan J, Bacar A, Abdallah KS, Attoumane R, Mliva AMSA, Zhong Y, Lu F, Song J. 2015. Polymorphisms of the artemisinin resistant marker (K13) in Plasmodium falciparum parasite populations of Grande Comore Island 10 years after artemisinin combination therapy. Parasites & Vectors, 8, 634. [CrossRef] [PubMed] [Google Scholar]
- Isozumi R, Uemura H, Kimata I, Ichinose Y, Logedi J, Omar AH, Kaneko A. 2015. Novel mutations in K13 propeller gene of artemisinin-resistant Plasmodium falciparum. Emerging Infectious Diseases, 21, 490–492. [CrossRef] [PubMed] [Google Scholar]
- Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, Mumba D, Kekre M, Yavo W, Mead D, Bouyou-Akotet M, Apinjoh T, Golassa L, Randrianarivelojosia M, Andagalu B, Maiga-Ascofare O, Amambua-Ngwa A, Tindana P, Ghansah A, MacInnis B, Kwiatkowski D, Djimde AA. 2015. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. Journal of Infectious Diseases, 211, 1352–1355. [Google Scholar]
- Kinde Gazard D, Ogouyèmi-Hounto A, Capo-Chichi L, Gbaguidi J, Massougbodji A. 2012. Essai clinique randomisé comparant l’efficacité et la tolérance de la combinaison Artémisinine–Naphthoquine (Arco®) et Artéméther–Luméfantrine (Coartem®) dans le traitement du paludisme simple au Bénin. Bulletin de la Société de Pathologie Exotique, 105, 208–214. [CrossRef] [Google Scholar]
- Maiga AW, Fofana B, Sagara I, Dembele D, Dara A, Traore OB, Toure S, Sanogo K, Dama S, Sidibe B, Kone A, Thera MA, Plowe CV, Doumbo OK, Djimde AA. 2012. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. American Journal of Tropical Medicine and Hygiene, 87, 23–28. [CrossRef] [Google Scholar]
- Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF, Thai CQ, Amambua-Ngwa A, Conway DJ, Djimdé AA, Doumbo OK, Zongo I, Ouedraogo JB, Alcock D, Drury E, Auburn S, Koch O, Sanders M, Hubbart C, Maslen G, Ruano-Rubio V, Jyothi D, Miles A, O’Brien J, Gamble C, Oyola SO, Rayner JC, Newbold CI, Berriman M, Spencer CC, McVean G, Day NP, White NJ, Bethell D, Dondorp AM, Plowe CV, Fairhurst RM, Kwiatkowski D. 2013. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genetics, 45, 648–655. [CrossRef] [PubMed] [Google Scholar]
- Mita T, Venkatesan M, Ohashi J, Culleton R, Takahashi N, Tsukahara T, Ndounga M, Dysoley L, Endo H, Hombhanje F, Ferreira MU, Plowe CV, Tanabe K. 2011. Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. Journal of Infectious Diseases, 204, 1980–1988. [CrossRef] [Google Scholar]
- Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, Orukan F, Arinaitwe E, Tappero JW, Kaharuza F, Kamya MR, Dorsey G. 2014. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malaria Journal, 13, 32–37. [CrossRef] [PubMed] [Google Scholar]
- Muwanguzi J, Henriques G, Sawa P, Bousema T, Sutherland CJ, Beshir KB. 2016. Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children. Malaria Journal, 15, 36. [CrossRef] [PubMed] [Google Scholar]
- Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. New England Journal of Medicine, 359, 2619–2620. [CrossRef] [PubMed] [Google Scholar]
- Ogouyèmi-Hounto A, Azandossessi C, Lawani S, Damien G, SissintoSavi de Tove Y, Remoue F, KindeGazard D. 2016. Therapeutic efficacy of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin. Malaria Journal, 15, 37. [CrossRef] [PubMed] [Google Scholar]
- Ogouyèmi-Hounto A, Ndam NK, Fadégnon G, Azagnandji C, Bello M, Moussiliou A, Chippaux JP, KindeGazard D, Massougbodji A. 2013. Low prevalence of the molecular markers of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in asymptomatic children in Northern Benin. Malaria Journal, 12, 413. [CrossRef] [PubMed] [Google Scholar]
- Ouattara A, Kone A, Adams M, Fofana B, Maiga AW, Hampton S, Coulibaly D, Thera MA, Diallo N, Dara A, Sagara I, Gil JP, Bjorkman A, Takala-Harrison S, Doumbo OK, Plowe CV, Djimde AA. 2015. Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, Mali. American Journal of Tropical Medicine and Hygiene, 92, 1202–1206. [CrossRef] [Google Scholar]
- Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F. 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet, 379, 1960–1966. [CrossRef] [PubMed] [Google Scholar]
- Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolatereductase: polymerase chain reaction methods for surveillance in Africa. American Journal of Tropical Medicine and Hygiene, 52, 565–568. [Google Scholar]
- Shayo A, Mandara CI, Shahada F, Buza J, Lemnge MM, Ishengoma DS. 2014. Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania. Malaria Journal, 13, 376. [CrossRef] [PubMed] [Google Scholar]
- Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp AM, Fukuda MM, Nosten F, Noedl H, Imwong M, Bethell D, Se Y, Lon C, Tyner SD, Saunders DL, Socheat D, Ariey F, Phyo AP, Starzengruber P, Fuehrer HP, Swoboda P, Stepniewska K, Flegg J, Arze C, Cerqueira GC, Silva JC, Ricklefs SM, Porcella SF, Stephens RM, Adams M, Kenefic LJ, Campino S, Auburn S, MacInnis B, Kwiatkowski DP, Su XZ, White NJ, Ringwald P, Plowe CV. 2013. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proceedings of the National Academy of Sciences USA, 110, 240–245. [CrossRef] [Google Scholar]
- Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM, Tagbor H, Williams J, Bojang K, Njie F, Desai M, Kariuki S, Gutman J, Mathanga DP, Mårtensson A, Ngasala B, Conrad MD, Rosenthal PJ, Tshefu AK, Moormann AM, Vulule JM, Doumbo OK, TerKuile FO, Meshnick SR, Bailey JA, Juliano JJ. 2015. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. Journal of Infectious Diseases, 211, 670–679. [CrossRef] [Google Scholar]
- Torrentino-Madamet M, Fall V, Benoit N, Camara C, Amalvict R, Fall M, DionneP Fall KB, Nakoulima A, Diatta B, Diemé Y, Ménard D, Wade B, Pradines B. 2014. Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012–2013. Malaria Journal, 13, 472. [CrossRef] [PubMed] [Google Scholar]
- Tine RCK, Faye B, Sylla K, Ndiaye JL, Ndiaye M, Sow D, Lo AC, Abiola A, Ba MC, Gaye O. 2012. Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial. Malaria Journal, 11, 416. [CrossRef] [PubMed] [Google Scholar]
- WHO. 2006. WHO guidelines for the treatment of malaria. World Health Organization: Geneva, Switzerland. [Google Scholar]
- Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, Magill AJ, Su XZ. 2002. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature, 418, 320–323. [CrossRef] [PubMed] [Google Scholar]
- Yadouléton A, N’guessan R, Allagbé H, Asidi A, Boko M, Osse R, Padonou G, Kindé G, Akogbéto M. 2010. The impact of the expansion of urban vegetable farming on malaria transmission in major cities of Benin. Parasites & Vectors, 3, 118. [CrossRef] [PubMed] [Google Scholar]
- Zwang J, Dorsey G, Mårtensson A, d’Alessandro U, Ndiaye JL, Karema C, Djimde A, Brasseur P, Sirima SB, Olliaro P. 2014. Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999–2009. Malaria Journal, 13, 114–119. [CrossRef] [PubMed] [Google Scholar]
Cite this article as: Ogouyèmi-Hounto A, Damien G, Deme AB, Ndam NT, Assohou C, Tchonlin D, Mama A, Hounkpe VO, Moutouama JD, Remoué F, Ndiaye D & Kindé Gazard D: Lack of artemisinin resistance in Plasmodium falciparum in northwest Benin after 10 years of use of artemisinin-based combination therapy. Parasite, 2016, 23, 28.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.